ADVI Analysis: MedPAC Meeting September 2023
The Medicare Payment Advisory Commission (MedPAC) held its latest meeting on September 7-8,, 2023 (link). The following relevant topics were discussed: Medicare Advantage: MedPAC workplan, Standardized benefits in Medicare Advantage Plans, and Improving MedPAC's estimate of Medicare Advantage Coding Intensity . Read the ADVI Angle on key takeaways.
MedPAC held a meeting September 7-8, 2023 (link). The following relevant topics were discussed:
- Medicare Advantage: MedPAC workplan
- Standardized benefits in Medicare Advantage plans
- Improving MedPAC’s estimate of Medicare Advantage coding intensity
ADVI Angle
The following are key takeaways from the September meeting:
- Medicare Advantage: MedPAC workplan
- Commissioners discussed the forthcoming analyses MedPAC will conduct and the chapters they will publish regarding Medicare Advantage (MA) plans, including an MA status report, standardizing MA benefits, and access/quality in MA
- Standardized benefits in Medicare Advantage plans
- Commissioners generally supported:
- (1) standardizing Part A and B cost sharing and a minimum level of dental, hearing, and vision benefits
- (2) limiting the number of plans that can be offered by each sponsor, and
- (3) applying standardization to conventional MA plans only
- Commissioners generally supported:
- Improving MedPAC’s estimate of Medicare Advantage Coding Intensity
- MedPAC staff presented several methodologies for estimating MA coding intensity, including the “Demographic estimate of coding intensity” (DECI) method, described in a 2021 non-MedPAC publication. Commissioners expressed concern about using one external methodology to estimate MA coding intensity and made broader suggestions related to coding
This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.
CEO insights
Related articles
Real analysis from people who’ve been there
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development
Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …
ADVI Analysis: HRSA 340B Covered Entity Audits
Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …
Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions
In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.